Today, Eli Lilly has announced positive top-line results from the TRAILBLAZER-ALZ2 Phase III #clinicaltrial of #donanemab in early #Alzheimer’s disease, which met its primary and all secondary endpoints.

We look forward to hearing more at #AAIC23.

https://www.alzheimer-europe.org/news/eli-lilly-announces-positive-top-line-results-trailblazer-alz2-trial-donanemab